Wolverine Trading’s Aldeyra Therapeutics ALDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-10,600
Closed -$40.2K 5579
2025
Q2
$40.2K Sell
10,600
-18,400
-63% -$47.6K ﹤0.01% 4391
2025
Q1
$193K Buy
29,000
+11,100
+62% +$65.6K ﹤0.01% 3973
2024
Q4
$89.9K Sell
17,900
-8,200
-31% -$42.1K ﹤0.01% 4828
2024
Q3
$144K Buy
+26,100
New +$124K ﹤0.01% 4238
2022
Q2
Sell
-19,900
Closed -$90K 4400
2022
Q1
$90K Sell
19,900
-2,300
-10% -$9.16K ﹤0.01% 4866
2021
Q4
$90K Buy
22,200
+4,600
+26% +$35.1K ﹤0.01% 5136
2021
Q3
$157K Buy
+17,600
New +$162K ﹤0.01% 5518

Other funds holding ALDX

Wolverine Trading's ALDX Position: Q2 2025 in Review

Wolverine Trading sold out of Aldeyra Therapeutics (ALDX) in Q2 2025, closing a stake of 12,028 shares — an estimated $31.1K sold.

Wolverine Trading first reported a position in ALDX in Q2 2022 and held it in 5 quarters. The position peaked at $209K in Q1 2023. 121 funds tracked by Wall St. Rank hold ALDX as of Q2 2025.

  • Wolverine Trading reported no remaining Aldeyra Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wolverine Trading sold 12,028 Aldeyra Therapeutics shares in Q2 2025, an estimated $31.1K.
  • Wolverine Trading first reported a position in Aldeyra Therapeutics in Q2 2022 and held it in 5 quarters.
  • Wolverine Trading's Aldeyra Therapeutics position peaked at $209K in Q1 2023.
  • 121 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2025.

Based on Wolverine Trading's 13F filing for Q2 2025, filed 18 Aug 2025.